• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 14D9/A filed by Olink Holding AB

    7/17/24 8:30:07 AM ET
    $OLK
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $OLK alert in real time by email
    SC 14D9/A 1 tm2419014d11_sc14d9a.htm SC 14D9/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 14D-9

    (Rule 14d-101)
    SOLICITATION/RECOMMENDATION STATEMENT
     

    UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 15)

     

     

     

    Olink Holding AB (publ)

    (Name of Subject Company)

     

     

     

    Olink Holding AB (publ)

    (Name of Person Filing Statement)

     

     

     

    American Depositary Shares, each representing one Common Share,
    quota value SEK 2.431906612623020 per share

    Common Shares, quota value SEK 2.431906612623020 per share

    (Title of Class of Securities)

     

    680710100*

    (CUSIP Number of Class of Securities)

     

    Olink Proteomics Inc.

    130 Turner St. Building 2, Suite 230

    Waltham, MA 02453, USA Tel: (617) 393-3933

    Attn: Linda Ramirez-Eaves, General Counsel

    (Name, address and telephone number of person authorized to receive notices and communications on behalf of the person(s) filing statement)

     

    With copies to:

     

    Mark Mandel, Esq. Piotr Korzynski, Esq.
    Baker & McKenzie LLP Baker & McKenzie LLP
    452 Fifth Avenue 300 East Randolph Street, Suite 5000
    New York, New York 10018 Chicago, IL 60601
    (212) 626-4100 (312) 861-8000

     

     

     

    ¨Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

     

     

    *This CUSIP number is assigned to the Subject Company’s American Depositary Shares, each representing one (1) Common Share.

     

     

     

     

     

    This Amendment No. 15 (this “Amendment”) amends and supplements the Solicitation/Recommendation Statement on Schedule 14D-9 (as amended or supplemented from time to time, the “Schedule 14D-9”) filed by Olink Holding AB (publ), a public limited liability company organized under the laws of Sweden (“Olink” or the “Company”), with the Securities and Exchange Commission (the “SEC”) on October 31, 2023, relating to the tender offer by Orion Acquisition AB, a private limited liability company organized under the laws of Sweden (“Buyer”) and a direct, wholly owned subsidiary of Thermo Fisher Scientific Inc., a Delaware corporation (“Thermo Fisher” or “Parent”), to acquire all of the outstanding common shares, quota value SEK 2.431906612623020 per share (the “Common Shares”) and all of the outstanding American Depositary Shares, each representing one Common Share (the “ADSs” and, together with the Common Shares, the “Offer Securities”), of the Company in exchange for $26.00 per Common Share, representing $26.00 per ADS, in cash, without interest, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 31, 2023 (together with any amendments or supplements thereto, the “Offer to Purchase”), and in the accompanying ADS Letter of Transmittal (together with any amendments or supplements thereto, the “ADS Letter of Transmittal”) and Acceptance Form for Shares (together with any amendments or supplements thereto, the “Acceptance Form”). The Offer to Purchase, the ADS Letter of Transmittal, and the Acceptance Form were originally filed as Exhibits (a)(1)(A), (a)(1)(B) and (a)(1)(C) to the Tender Offer Statement filed under cover of Schedule TO with the SEC on October 31, 2023, by Thermo Fisher, with the amended and restated Offer to Purchase having been filed as Exhibit (A)(1)(H) under cover of Schedule TO with the SEC on December 1, 2023, by Thermo Fisher.

     

    Except to the extent specifically provided in this Amendment, the information set forth in the Schedule 14D-9 remains unchanged. Capitalized terms used, but not otherwise defined, in this Amendment have the meanings ascribed to them in the Schedule 14D-9. This Amendment is being filed to amend and supplement the Items set forth below.

     

    Item 2. Identity and Background of Filing Person.

     

    Item 2. “Identity and Background of Filing Person—(b) Tender Offer—The Offer” of the Schedule 14D-9 is hereby amended and supplemented to include the following:

     

    The Subsequent Offer Period expired at 5:00 p.m., New York City Time, on July 16, 2024.

     

     

     

    SIGNATURE

     

    After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule 14D-9 is true, complete and correct.

     

      OLINK HOLDING AB (PUBL)
       
    Date: July 17, 2024 By: /s/ Jon Heimer
        Name: Jon Heimer
        Title: Chief Executive Officer

     

     

    Get the next $OLK alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $OLK

    DatePrice TargetRatingAnalyst
    1/5/2023$27.00Sector Outperform
    Scotiabank
    12/14/2022$28.00Buy
    Canaccord Genuity
    2/14/2022$33.00 → $32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $OLK
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Notice to attend the Extra General Meeting of Olink Holding AB (publ)

      This is a translation of the Swedish original. In case of any discrepancies between this translation and the Swedish original, the latter shall prevail. UPPSALA, Sweden, July 11, 2024 (GLOBE NEWSWIRE) -- The shareholders of Olink Holding AB (publ) (the "Company"), reg. no. 559189-7755, are hereby given notice to attend the Extra General Meeting to be held at 4:00 p.m. CEST on Tuesday 6 August 2024, in the Company's facilities at Salagatan 16F, Uppsala. Registration for the meeting commences at 3:30 p.m. CEST. NOTICE OF PARTICIPATION Shareholders who wish to attend in the proceedings of the Extra General Meeting must: be entered in the share register kept on behalf of the Company by Eur

      7/11/24 4:05:45 PM ET
      $OLK
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Thermo Fisher Scientific Completes Acquisition of Olink, Announces Commencement of Subsequent Offering Period

      Subsequent Offering Period Scheduled to Expire at 5:00 p.m., New York Time, on July 16, 2024 Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced that it has completed its acquisition of Olink Holding AB (publ) ("Olink") (NASDAQ:OLK), a leading provider of next-generation proteomics solutions. The transaction values Olink at approximately $3.1 billion, net of $96 million of acquired cash. Olink will become part of Thermo Fisher's Life Sciences Solutions segment. "We are excited to welcome Olink colleagues to Thermo Fisher," said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher. "Protein research

      7/10/24 8:00:00 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components
    • Olink Announces Receipt of CMA Clearance for Proposed Acquisition by Thermo Fisher

      UPPSALA, Sweden, July 08, 2024 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) ("Olink") (NASDAQ:OLK) today announced that the UK Competition and Markets Authority (the "CMA") has unconditionally approved the previously announced tender offer (the "Offer") by Orion Acquisition AB (the "Buyer"), a wholly owned subsidiary of Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher" or "Parent"), for all outstanding Common Shares and American Depositary Shares (together, the "Shares") of Olink for $26.00 per Share. The Offer is being made pursuant to the Purchase Agreement, dated as of October 17, 2023, by and between Thermo Fisher and Olink. As a result of the CMA approval, Olink and Thermo Fis

      7/8/24 7:37:45 AM ET
      $OLK
      $TMO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Industrial Machinery/Components